Aurobindo Pharma Receives USFDA Approval for Dextromethorphan Cough Suspension
Aurobindo Pharma has secured USFDA final approval for its Dextromethorphan Polistirex Extended-Release Oral Suspension, an over-the-counter cough medication bioequivalent to Delsym. The product targets a US$ 138 million market and will be manufactured at the company's wholly-owned subsidiary APL Healthcare Limited, with commercial launch planned for Q2FY27.
*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma has received final approval from the United States Food and Drug Administration (USFDA) for its Dextromethorphan Polistirex Extended-Release Oral Suspension. The approved over-the-counter (OTC) formulation contains 30 mg of the active ingredient per 5 ml of suspension and is bioequivalent to the reference listed drug Delsym Extended-Release Oral Suspension.
Product Specifications and Market Details
The newly approved medication is designed to provide extended relief from cough symptoms. The following table outlines the key product and market details:
| Parameter: | Details |
|---|---|
| Active Ingredient: | Dextromethorphan Polistirex |
| Concentration: | 30 mg/5 ml |
| Formulation: | Extended-Release Oral Suspension (OTC) |
| Reference Drug: | Delsym Extended-Release Oral Suspension |
| Market Size: | US$ 138 million (12 months ending February 2026) |
| Launch Timeline: | Q2FY27 |
Manufacturing and Portfolio Impact
The product will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma. This approval brings the company's total ANDA approvals from USFDA to 580, comprising 557 final approvals and 23 tentative approvals.
The extended-release oral suspension temporarily relieves cough due to minor throat and bronchial irritation associated with common cold or inhaled irritants, and helps suppress the impulse to cough for better sleep.
Market Implications
With an estimated market size of US$ 138 million according to Nielsen data, this approval enables Aurobindo Pharma to enter a significant segment of the US cough medication market. The OTC nature of the product allows for broader market accessibility without prescription requirements, potentially contributing to the company's revenue growth from the American market.
Regulatory Significance
Receiving USFDA approval demonstrates that Aurobindo Pharma's manufacturing processes and product quality meet stringent American regulatory standards. The bioequivalence to the established reference drug Delsym further validates the therapeutic effectiveness of the company's formulation, strengthening its position in the competitive US pharmaceutical market.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.04% | +3.40% | +8.32% | +25.28% | +22.29% | +45.44% |
How will Aurobindo Pharma's entry into the $138 million US cough medication market affect pricing dynamics and competition with existing players like Delsym?
What impact could this OTC approval have on Aurobindo Pharma's overall US revenue mix and margins compared to their prescription drug portfolio?
Will Aurobindo Pharma leverage this extended-release technology platform to develop similar formulations for other therapeutic areas?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
